Sagar Lonial Sells 5,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) Stock

TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now directly owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX opened at $30.85 on Friday. The firm has a 50 day moving average of $24.59 and a 200 day moving average of $20.96. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The firm has a market capitalization of $4.80 billion, a price-to-earnings ratio of -308.45 and a beta of 2.19. TG Therapeutics, Inc. has a 12-month low of $10.82 and a 12-month high of $36.50.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.73 earnings per share. On average, research analysts anticipate that TG Therapeutics, Inc. will post 0.17 earnings per share for the current year.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds have recently modified their holdings of the company. NBC Securities Inc. boosted its position in shares of TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 485 shares during the period. Quarry LP boosted its position in shares of TG Therapeutics by 9.1% during the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 503 shares during the last quarter. Private Advisor Group LLC boosted its position in shares of TG Therapeutics by 3.9% during the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after acquiring an additional 542 shares during the last quarter. Blue Trust Inc. boosted its position in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 849 shares during the last quarter. Finally, KBC Group NV boosted its position in shares of TG Therapeutics by 30.5% during the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,092 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. TD Cowen assumed coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company. The Goldman Sachs Group boosted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. HC Wainwright boosted their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, B. Riley boosted their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.